Brand Name(s): CI-1011
CAS nş: 166518-60-1
(a vah si mide)
About Avasimibe
This new site is dedicated exclusively to avasimibe.
It offers you the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about avasimibe on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site also provides you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total avasimibe experience!
Why is this medication prescribed?
Avasimibe is an ACAT (acyl-coenzyme A: cholesterol acyltransferase) inhibitor that was developed to treat heart disease, prevent the progression of atherosclerosis, as well as lower cholesterol.
After having undergone the phase III clinical trials in 2002, Pfizer decided to discontinue its development.
Latest News
Atherosclerosis Symptoms, Causes, prevention and Treatment
By atherosclerosis the inside of the arteries are thickened, hardened and stiffened, causing the...
[more]Failure of ACAT Inhibition to Retard Atherosclerosis
Medical management of atherosclerosis is based on the control of its risk factors (dyslipidemia,...
[more]ACAT inhibitor unsuccessful at limiting atherosclerosis
Trial findings released last week at the American Heart Association scientific sessions 2005 in...
[more]Pfizer's Cardiovascular Failure
New York - Nobody wins all the time--not even the world's largest drug company. Yet Pfizer's...
[more]